INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 425m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
SEC FORM 4/Open-market purchaseVerified data

Marshall Richard Peter bought SER

Director · Serina Therapeutics, Inc. · Common Stock

Side
BUY
Value
$20K
Shares
12.2K
Price
$1.65
Executed
May 19, 2026
Disclosed
May 22, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
May 19 executedMay 22, 2026 disclosed

SER · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
47/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+13 / 25

    $20K reported value · new position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SER

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    MP
    Marshall Richard PeterDirector
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    15.3K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    15
    TS
    Tenjarla SriniSVP, CMC & Formulation
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    85.6K sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    19
    TS
    Tenjarla SriniSVP, CMC & Formulation
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    69.0K sh
    		Feb 3, 2026Feb 17, 2026
    traded Feb 3, 2026
    		+14dSEC FORM 4

    Evidence

    9
    BK
    Brannan Stephen K.Director
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    10.0K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    9
    MP
    Marshall Richard PeterDirector
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    10.0K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002016188-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 19, 2026
    Published
    May 22, 2026
    Ingested by INSIDER
    Nov 5, 03:57 UTC
    Last re-read
    Nov 5, 03:57 UTC

    Extracted facts

    Filer
    Marshall Richard Peter
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Serina Therapeutics, Inc.
    Ticker
    SER
    Shares
    12.2K
    Price per share
    $1.65
    Value
    $20,102
    Execution date (reported)
    May 19, 2026
    Owned after transaction
    12.2K shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 12.2K
    • Price: $1.65

    = $20,102

    What this establishes

    Marshall Richard Peter filed this Form 4 reporting a open-market purchase of SER on May 19, 2026. It became public on May 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Marshall Richard Petercik:0002016188
    Issuer
    Serina Therapeutics, Inc.cik:0001708599

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.